Immunological screening of Lassa Virus among Health workers and Contacts of patients of Lassa fever in Ondo State.


Journal

Immunobiology
ISSN: 1878-3279
Titre abrégé: Immunobiology
Pays: Netherlands
ID NLM: 8002742

Informations de publication

Date de publication:
05 2021
Historique:
received: 21 10 2020
revised: 18 02 2021
accepted: 27 02 2021
pubmed: 11 3 2021
medline: 20 1 2022
entrez: 10 3 2021
Statut: ppublish

Résumé

The increasing trends of morbidity and mortality of Lassa fever is becoming more alarming in Nigeria. Information about immune response to the virus is limited. At exposure, the level of immunity plays a vital role in the vulnerability of individuals infected. Investigating the immune status of health workers, infected cases and contacts of infected cases of Lassa fever in Ondo State. Blood samples were collected from 233 individuals comprising 102 health workers, 22 infected cases and 109 contacts of infected cases from Owo and Ose Local Government Areas and transported in triple level packaging. Plasma samples were analyzed for IgG and IgM markers using ReLASV® Pan-Lassa NP IgG/IgM ELISA Kit (Zalgen Labs, LLC, USA) while RNAs extracted from IgM positive samples were analyzed for LASV RNA according to manufacturers' instructions. Among the health workers, 20/102 (19.6%) and 2/102 (2.0%) were IgG and IgM positive respectively. While 16/22 (72.7%) and 14/22 (63.6%) were IgG and IgM positive respectively among the infected cases. Of the contacts of infected cases screened, 64/109 (58.7%) were IgG positive while 4/109 (3.7%) were positive for IgM. There was no detectable LASV RNA in the samples analyzed. These findings suggest that majority of the health workers are naïve to the virus and hence may be prone to the viral infection. It could also be suggestive that a good personal protective procedure is been practiced by the health workers, hence the low exposure. However, most of the contacts of infected cases show exposure to the virus.

Sections du résumé

BACKGROUND
The increasing trends of morbidity and mortality of Lassa fever is becoming more alarming in Nigeria. Information about immune response to the virus is limited. At exposure, the level of immunity plays a vital role in the vulnerability of individuals infected.
OBJECTIVE
Investigating the immune status of health workers, infected cases and contacts of infected cases of Lassa fever in Ondo State.
STUDY DESIGN
Blood samples were collected from 233 individuals comprising 102 health workers, 22 infected cases and 109 contacts of infected cases from Owo and Ose Local Government Areas and transported in triple level packaging. Plasma samples were analyzed for IgG and IgM markers using ReLASV® Pan-Lassa NP IgG/IgM ELISA Kit (Zalgen Labs, LLC, USA) while RNAs extracted from IgM positive samples were analyzed for LASV RNA according to manufacturers' instructions.
RESULT
Among the health workers, 20/102 (19.6%) and 2/102 (2.0%) were IgG and IgM positive respectively. While 16/22 (72.7%) and 14/22 (63.6%) were IgG and IgM positive respectively among the infected cases. Of the contacts of infected cases screened, 64/109 (58.7%) were IgG positive while 4/109 (3.7%) were positive for IgM. There was no detectable LASV RNA in the samples analyzed.
CONCLUSION
These findings suggest that majority of the health workers are naïve to the virus and hence may be prone to the viral infection. It could also be suggestive that a good personal protective procedure is been practiced by the health workers, hence the low exposure. However, most of the contacts of infected cases show exposure to the virus.

Identifiants

pubmed: 33689957
pii: S0171-2985(21)00024-3
doi: 10.1016/j.imbio.2021.152076
pii:
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

152076

Informations de copyright

Copyright © 2021. Published by Elsevier GmbH.

Auteurs

Joseph Ojonugwa Shaibu (JO)

Centre for Human Virology and Genomics Research, Microbiology Department, Nigerian Institute of Medical Research, 6 Edmond Crescent, P.M.B 2013, Yaba 101012, Lagos, Nigeria. Electronic address: josephshaibu2013@gmail.com.

Olumuyiwa Babalola Salu (OB)

Centre for Human and Zoonotic Virology, Central Research Laboratory and the Department of Medical Microbiology and Parasitology, College of Medicine, University of Lagos, PM.B. 12003, Idi-Araba, Surulere, Lagos, Nigeria.

Olufemi Samuel Amoo (OS)

Centre for Human Virology and Genomics Research, Microbiology Department, Nigerian Institute of Medical Research, 6 Edmond Crescent, P.M.B 2013, Yaba 101012, Lagos, Nigeria.

Ifeoma Idigbe (I)

Clinical Sciences Department, Nigerian Institute of Medical Research, 6 Edmond Crescent, P.M.B 2013, Yaba 101012, Lagos, Nigeria.

Adesola Zaidat Musa (AZ)

Clinical Sciences Department, Nigerian Institute of Medical Research, 6 Edmond Crescent, P.M.B 2013, Yaba 101012, Lagos, Nigeria.

Oliver Chukwujekwu Ezechi (OC)

Clinical Sciences Department, Nigerian Institute of Medical Research, 6 Edmond Crescent, P.M.B 2013, Yaba 101012, Lagos, Nigeria.

Chukwuyem Abejegah (C)

Infection Control and Research Centre, Federal Medical Centre, Owo, Ondo State, Nigeria.

Oluwafemi Ayodeji (O)

Infection Control and Research Centre, Federal Medical Centre, Owo, Ondo State, Nigeria.

Babatunde Lawal Salako (BL)

Clinical Sciences Department, Nigerian Institute of Medical Research, 6 Edmond Crescent, P.M.B 2013, Yaba 101012, Lagos, Nigeria.

Sunday Aremu Omilabu (SA)

Centre for Human Virology and Genomics Research, Microbiology Department, Nigerian Institute of Medical Research, 6 Edmond Crescent, P.M.B 2013, Yaba 101012, Lagos, Nigeria; Centre for Human and Zoonotic Virology, Central Research Laboratory and the Department of Medical Microbiology and Parasitology, College of Medicine, University of Lagos, PM.B. 12003, Idi-Araba, Surulere, Lagos, Nigeria.

Rosemary Ajuma Audu (RA)

Centre for Human Virology and Genomics Research, Microbiology Department, Nigerian Institute of Medical Research, 6 Edmond Crescent, P.M.B 2013, Yaba 101012, Lagos, Nigeria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH